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It will come as no surprise to most clinicians involved in the
treatment of primary brain tumours that there is little evidence of
improvement in outcome between the late 1980s and the late
1990s. The majority of these tumours are gliomas and in this group
most are high-grade tumours, which are notorious for having
resisted the therapeutic endeavours that have improved outcome
in so many other cancers. It is only in the last few years that new
insights into the biology of gliomas and significant changes in the
treatment of these tumours has occurred, which we predict will
alter the outcome in the coming decade.
High-grade glial tumours typically present with a short history
of focal neurological deficit, which progresses over days to weeks
and may mimic a stroke-like illness. In most cases, a space-
occupying lesion can be demonstrated on CT or MRI scanning and
the diagnosis is confirmed by biopsy and/or resection, which is
always subtotal because of the infiltrating nature of the disease.
The much wider use of high-quality CT and MRI scans in patients
presenting in this way during the late 1980s and 1990s accounts for
some of the increased incidence of brain tumours reported during
this time. During the same period, the classification of tumour
subtypes was clarified in a new WHO classification in which
glioblastoma was formally grouped with astrocytic tumours, but
no major changes in disease definition occurred (Kleihues et al,
1993; Louis et al, 2007).
In Europe, the standard approach to management of these
tumours, which has persisted until very recently has been maximal
surgery followed by external beam radiotherapy. The influence of
the extent of surgery has never been addressed in a randomised
study although many series have suggested that it is a prognostic
indicator (Wrensch et al, 2006). It is likely that improvements in
surgical technique, particularly the use of stereotactic biopsy
also contributed to more frequent diagnosis of tumour during
this time period, but made little impact on outcome. During
this time, the development of radiotherapy technology also meant
that more patients were treated using CT-based techniques
to improve definition and verification of the tumour target as
well as radiation dosimetry. However, because of the apparent
inherent radioresistance of these tumours these advances did not
impact significantly on outcomes (Oppitz et al, 1999; Chan et al,
2002).
Against this background, the observed increase in incidence but
lack of improvement in survival is not surprising. The fact that the
overall survival (OS) actually worsened is probably because of
increased diagnosis in patient groups that carry the worst
prognosis, particularly the elderly and those with a poor
performance status. The reversal of the deprivation gap is also
most easily explained, as the authors suggest, by differences in
access to imaging and diagnostic services so that the more affluent
groups were more likely to be correctly diagnosed with a tumour,
but in circumstances in which their prognosis remained very poor.
The rather depressing statistics presented in this paper make it
clear that improvements in diagnosis and in technical aspects of
treatment that occurred during the late 1980s and 1990s were
insufficient to improve the outcome for brain tumour patients.
More recently, however, the approach to diagnosis and treatment
of these tumours has changed and there is now optimism that OS
is beginning to improve in some tumour types. Advances in
molecular techniques have allowed the definition of tumour
subtypes that respond differently to treatment. Most significantly,
it has been recognised that some glial tumours with specific
chromosome abnormalities, particularly oligodendrogliomas with
loss of 1p19q, respond favourably to chemotherapy and radio-
therapy and represent a significantly better prognostic group
(Cairncross et al, 2006; van den Bent et al, 2006). This has
prompted ongoing investigation into the relevance of other genetic
markers in gliomas and considerable effort is going in to
identifying genomic profiles that may be useful as predictive or
prognostic indicators (Dehais et al, 2006).
The most significant advance in treatment of glioma has been
the demonstration that in grade IV tumours (glioblastoma), the
addition of concomitant and adjuvant chemotherapy with
temozolomide to postoperative radiotherapy can improve OS
(Stupp et al, 2005). In this randomised study, patients allocated to
temozolomide given continuously during radiotherapy and for
an additional 6 months thereafter had median survival of
14.6 months compared with 12.1 months in the group treated
with radiotherapy only and 2-year survivorship was increased
from 11 to 26%. In a parallel translational study, the activity of
the DNA repair enzyme MGMT was measured in tumour tissue.
These data suggested that response to temozolomide may depend
on the activity of this enzyme, as patients with methylation of the
promoter region for the gene and therefore reduced activity levels,
showed more benefit from the addition of temozolomide (Hegi
et al, 2005). Ongoing studies will address the utility of this
approach in other tumour types and contribute further to our
understanding of the impact of tumour genotype and epigenetics
on response to specific treatments. In parallel with the successful
application of molecularly targeted agents in other tumours, the
role of drugs that can target specifically upregulated growth factor
pathways are also being explored in gliomas (Mellinghoff et al,
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neurosurgical and radiotherapy technology.
The development of new individualised approaches to treating
these tumours will mean that coordination between neuropatho-
logists and the multidisciplinary team responsible for managing
these patients will become essential for treatment optimisation.
It will also provide an impetus to include more of these
patients in well-designed clinical studies that can further
define the role of specific interventions in well-defined tumour
subgroups.
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